Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

Related Articles by Review for PubMed (Select 19301902)

1.

Design of chimeric histone deacetylase- and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rbeta, and histone deacetylases.

Mahboobi S, Dove S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T.

J Med Chem. 2009 Apr 23;52(8):2265-79. doi: 10.1021/jm800988r.

PMID:
19301902
2.

The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.

Deadman BJ, Hopkin MD, Baxendale IR, Ley SV.

Org Biomol Chem. 2013 Mar 21;11(11):1766-800. doi: 10.1039/c2ob27003j. Epub 2012 Dec 18. Review.

PMID:
23247657
3.

Imatinib: a selective tyrosine kinase inhibitor.

Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, Meyer T, Zimmermann J.

Eur J Cancer. 2002 Sep;38 Suppl 5:S19-27. Review.

PMID:
12528769
4.

The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.

Eck MJ, Manley PW.

Curr Opin Cell Biol. 2009 Apr;21(2):288-95. doi: 10.1016/j.ceb.2009.01.014. Epub 2009 Feb 11. Review.

PMID:
19217274
5.

Lessons learned from the development of imatinib.

Lydon NB, Druker BJ.

Leuk Res. 2004 May;28 Suppl 1:S29-38. Review. No abstract available.

PMID:
15036939
6.

Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.

Mol CD, Fabbro D, Hosfield DJ.

Curr Opin Drug Discov Devel. 2004 Sep;7(5):639-48. Review.

PMID:
15503866
7.

Resistance to tyrosine kinase inhibitors: calling on extra forces.

Cools J, Maertens C, Marynen P.

Drug Resist Updat. 2005 Jun;8(3):119-29. Review.

PMID:
15869901
8.
9.

Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor.

Le Tourneau C, Siu LL.

Expert Opin Investig Drugs. 2008 Aug;17(8):1247-54. doi: 10.1517/13543784.17.8.1247 . Review.

PMID:
18616420
10.

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G.

Curr Drug Targets. 2009 Jun;10(6):530-6. Review.

PMID:
19519355
11.

Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents.

Moradei O, Vaisburg A, Martell RE.

Curr Top Med Chem. 2008;8(10):841-58. Review.

PMID:
18673170
12.

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges.

Atadja P.

Cancer Lett. 2009 Aug 8;280(2):233-41. doi: 10.1016/j.canlet.2009.02.019. Epub 2009 Apr 2. Review.

PMID:
19344997
13.

Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders.

Wiech NL, Fisher JF, Helquist P, Wiest O.

Curr Top Med Chem. 2009;9(3):257-71. Review.

PMID:
19355990
14.

ABL1 fusions in T-cell acute lymphoblastic leukemia.

De Keersmaecker K.

Verh K Acad Geneeskd Belg. 2008;70(4):245-55. Review.

PMID:
19166098
15.

Histone deacetylase inhibitors for epigenetic therapy of cancer.

Monneret C.

Anticancer Drugs. 2007 Apr;18(4):363-70. Review. Erratum in: Anticancer Drugs. 2007 Jun;18(5):219.

PMID:
17351388
16.

Hypereosinophilic syndrome: diagnosis and treatment.

Peros-Golubicić T, Smojver-Jezek S.

Curr Opin Pulm Med. 2007 Sep;13(5):422-7. Review.

PMID:
17940488
17.

The role of histone deacetylases (HDACs) in human cancer.

Ropero S, Esteller M.

Mol Oncol. 2007 Jun;1(1):19-25. doi: 10.1016/j.molonc.2007.01.001. Epub 2007 Mar 7. Review.

18.

Synthetic routes and biological evaluation of largazole and its analogues as potent histone deacetylase inhibitors.

Li S, Yao H, Xu J, Jiang S.

Molecules. 2011 Jun 7;16(6):4681-94. doi: 10.3390/molecules16064681. Review.

19.

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy.

Thomas S, Munster PN.

Cancer Lett. 2009 Aug 8;280(2):184-91. doi: 10.1016/j.canlet.2008.12.026. Epub 2009 Jan 30. Review.

PMID:
19185986
20.

Explorative study on isoform-selective histone deacetylase inhibitors.

Suzuki T.

Chem Pharm Bull (Tokyo). 2009 Sep;57(9):897-906. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk